For the upcoming 2020-2021 flu season, CPP members will have
two opportunities to save on influenza vaccines:
SANOFI PASTEUR: CPP members who confirm their flu vaccine reservation on VaccineShoppe.com by the March 31, 2020 deadline will receive the discounted member pricing, delivery commitments and returns allowance. Please also note that CPP members can now earn an additional 1% rebate from CPP on all Sanofi Pasteur flu vaccine purchases! To receive these benefits, make sure your Sanofi Pasteur account is linked to the CPP member pricing and confirm your reservation through www.VaccineShoppe.com by the deadline.
ASTRAZENECA: Members who wish to pre-book FluMist doses will have an opportunity to purchase them at a discount, receive a returns allowance and a supply commitment. To receive these benefits, confirm that the DEA # for your practice is linked to CPP by submitting a declaration form and pre-book your FluMist doses through your preferred authorized distributor by January 31, 2020 (Early Pre-Book for a larger discount) or March 31, 2020 (Standard Pre-Book). Declaration forms can be obtained by contacting the CPP office.
Immunization Action Coalition is offering several options to display your support for immunizations. The “Vaccines Save Lives” pin is black enamel with gold lettering and is small enough to fit on a lapel. Prices range from $20 for a single pin to $5.25 each when ordering 15 or more.
Flu Vaccine Buttons and Stickers are available for staff and patients. Order buttons for staff to show that flu vaccine is available in your clinic. Buttons are sold in bags of 10 and range from $20 for one bag to $55 for 10 bags. Purchase stickers for patients to wear after receiving their flu shot. Stickers are sold in bundles of 100 and range from $23 for one bundle to $67 for 10 bundles. All prices include shipping.
All staff in a pediatric practice, including non-clinical
staff, play an important role in supporting parents in their immunization
decisions. Creating a culture of immunization in your office helps promote
complete and timely immunizations. To that end, the CDC and Sanofi Pasteur have
produced helpful resources to aid in building a pro-vaccination culture.
Flu vaccine efficacy varies from year to year depending on
the similarity of the flu viruses the vaccine is designed to prevent and the
flu viruses in the community. However, recent studies show that have supported
the conclusion that flu vaccination benefits public health. The CDC recommends
that everyone age 6 months and older receive a flu vaccine yearly by the end of
October. Benefits of vaccination
contracting the flu. In seasons where the vaccine is well matched, it
reduces the risk of having to visit the doctor with flu by 40
percent to 60 percent.
the severity of flu if contracted. A 2018 study showed that among adults
hospitalized with flu vaccinated patients were 59 percent less likely to be admitted
to the ICU.
Quadrivalent Influenza Vaccine is an injectable immunization approved for
patients 6 months and up. Fluzone is an inactivated vaccine protecting against
four strains of the flu. In addition, Fluzone is approved for pregnant women.
Another option for flu is FluMist Quadrivalent, which is
a nasal-spray flu vaccine approved for ages 2 through 49. FluMist is a live
attenuated influenza vaccine and is not for use in pregnant women.
For some, the flu is a mild illness. For older adults,
especially those with chronic health conditions such as diabetes or heart
disease, the flu can be far more serious. Older adults are at high-risk to
complications from the flu such as pneumonia. It’s estimated that
between 70 and 90 percent of flu related dates occurred in people over 65, and
between 50 and 70 percent of seasonal-flu related hospitalizations occur in
that age group. Adults age 50 to 64 can choose from any available flu vaccine.
For adults 65 and older, the CDC recommends one of two vaccines developed specifically
for that age group: the high dose flu
vaccine and the adjuvanted flu
The high dose vaccine, Fluzone
High Dose, delivers 4X the amount of antigen as the regular dose Fluzone
vaccine. Compared to Fluzone, Fluzone High dose provides between 24%1 and
51%2 better protection from influenza.
The adjuvanted vaccine, Flublok
Quadrivalent, is approved for persons ages 18 and older. Flublok has 3X the
HA of a standard-dose quadrivalent inactivated influenza vaccine. Flublock also
prevents more cases of flu in adults 50+ than a standard-dose quadrivalent
vaccine. People over 65 should talk to their doctor about the pneumococcal vaccination,
which can help prevent pneumococcal pneumonia,
a serious flu-related complication.
Earlier this month, the AAP released their updated recommendations
for the use of influenza vaccines and antiviral medications in children. These
include no preference for the inactivated or live attenuated vaccine, updated
guidelines for children receiving their first flu vaccine, and information
about a new antiviral medication. The recommendations can be viewed
1 24.2% Primary endpoint: the occurrence of laboratory-confirmed,
protocol-defined, influenza-like illness caused by viral strains regardless of
their antigenic similarity to vaccine components.
2 51.1% Secondary endpoint: the occurrence of
culture-confirmed influenza caused by viral types/subtypes antigenically
similar to those contained in the respective annual vaccine formulations in
association with a modified Centers for Disease Control and Prevention-defined
The Immunization Action Coalition and Sanofi Pasteur have
collaborated a project to raise awareness of the low immunization rates for the
meningococcal (MenACWY) vaccination. The project, titled “MenACWY: You’re Not
Done if You Give Just One,” can be found at https://www.give2menacwy.org/ and
contains a wealth of resources for medical practices.
The facts are stark: Meningococcal disease can be deadly,
and survivors can suffer lifelong disabilities from contracting the disease.
Unfortunately, the majority of administration opportunities are missed. Even
during vaccine only visits, 86% of adolescents were not given MenACWY. 1
The recommended administration guidelines are to give the
initial dose at 11-12 years of age and the second dose at 16 years of age. This factsheet
provides important information about recommending and administering MenACWY.
In the upcoming months, CPP will continue posting resources
on increasing adolescent immunization rates and creating a culture of
vaccination in your practice. Subscribe to our blog to stay up to date.
1. Wong CA. Taylor JA, Wright JA, et al. Missed
opportunities for adolescent vaccination, 2006–2011. J Adolesc Health.
On Wednesday, August 28, the CDC will be hosting a webinar
from 1-2pm to assist providers in recommending vaccines and addressing vaccine
Speakers for the webinar include:
Dr. Amanda Cohn, Acting Chief Medical Officer,
Vaccine Policy, Preparedness, Global Health, National Center for Immunization
and Respiratory Diseases, Centers for Disease Control and Prevention
Chanie Sternberg, President & CEO,
Dr. Corinna Manini, Chief Medical Officer,
Dr. Todd Wolynn, CEO, Kids Plus Pediatrics
RefuahHealth is a health center in New York that serves
patients in communities affected by ongoing measles outbreaks. They have worked
to cultivate trust with parents concerning the safety and efficacy of vaccines.
this link for more information and to register. Don’t wait to register for
this timely and relevant information. And stay tuned to the CPP Blog. In the
next few months, we will be posting a series on addressing vaccine hesitancy in
your practice. Subscribe to our blog to stay up to date!
Sanofi Pasteur has put together a wealth of coding resources
for the 2019-2020 flu season. Coding and billing for vaccinations can be
complicated, so these resources are designed to save your practice time.
Sanofi has scheduled two webinars to assist in flu coding.
One is targeted at coding for patients of any age, and the other is
specifically for pediatric patients. The all ages webinar is scheduled for
August 20 and September 12, 18, and 19. The pediatric webinar is scheduled for
August 21 and September 10. The webinar will cover essential coding and billing
information, Medicaid billing and VFC, Medicare billing, and payment
The second guide, 2019-2020
Proper Codes of Sanofi Pasteur Products, includes product codes, NDCs in
billing format, IDC-10 codes, administration codes, and CVX codes for each
vaccine. It has been updated to include this year’s flu vaccinations.
Medical Economics recently published an article highlighting
the benefits of partnering with a group purchasing organization (GPO) or
physician buying group (PBG). Practices can expect savings ranging from 5
percent to 25 percent by joining such a group. Highlights include:
Don’t base your GPO choice on what your hospital
uses. Physician offices have different needs than hospitals. Find a group that
fits your specific needs.
Revisit pricing every year or two and compare
groups. The needs of a practice can change over time, and there is no one size
fits all solution.
Know the difference between a GPO and PBG. GPOs
are membership organizations that offer discounts on most everything involved
in a medical practice such as capital equipment, supplies, and services. PBGs
also offer discounts on supplies and services, but they primarily serve as
vaccine buying groups. Due to their vaccine focus, PBGs are able to provide
Let your vendors do the work of pricing. Put
your top purchased items out for bid to ensure you are getting the best price.
Check if your distributor performs additional
services like stocking and ordering supplies.
This post is
the second in a series on increasing adolescent immunizations. For a case study
on how one health system increased their overall adolescent vaccination rates,
see our previous post.
The CPP 2nd Dose Program provides an opportunity to examine your practice’s 2nd dose immunization rates for vaccines that require more than one dose to complete the series, access resources to help implement a strategy in your office to raise those rates, and share successful strategies with other CPP members. Applicable vaccines include meningococcal ACWY, HPV, adult pneumococcal and/or adult hepatitis B (Heplisav-B only).
The tables below show immunization rates for these vaccines for the most recent year available from the CDC:
in CPP’s 2nd Dose Program have already seen successes. Over 77%
of member participants reported that their 2nd dose immunization rates were
lower than they expected when they pulled the initial data from their
EMR. After implementing an intervention in their practice to help improve
these rates, participants saw a rise in their HPV and MCV4 completion rates by an
average of 29% and 41%, respectively!
best practices that were shared by the group include: